GT Biopharma, Inc. Quarterly Operating Income (Loss) in USD from Q2 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
GT Biopharma, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2010 to Q3 2024.
  • GT Biopharma, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$3.6M, a 15.4% decline year-over-year.
  • GT Biopharma, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$13.8M, a 14.9% increase year-over-year.
  • GT Biopharma, Inc. annual Operating Income (Loss) for 2023 was -$13.6M, a 36.1% increase from 2022.
  • GT Biopharma, Inc. annual Operating Income (Loss) for 2022 was -$21.3M, a 63% increase from 2021.
  • GT Biopharma, Inc. annual Operating Income (Loss) for 2021 was -$57.5M, a 750% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$13.8M -$3.6M -$482K -15.4% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$13.3M -$3.91M -$285K -7.87% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$13M -$3.09M +$574K +15.7% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 -$13.6M -$3.17M +$2.61M +45.2% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-26
Q3 2023 -$16.2M -$3.12M +$3.9M +55.5% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$20.1M -$3.62M -$607K -20.1% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$19.5M -$3.67M +$1.78M +32.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 -$21.3M -$5.78M +$12.4M +68.2% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-26
Q3 2022 -$33.7M -$7.02M -$1.07M -18% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-01
Q2 2022 -$32.6M -$3.01M +$1.37M +31.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 -$34M -$5.44M +$23.6M +81.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$57.5M -$18.2M -$13.8M -320% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-30
Q3 2021 -$43.7M -$5.95M -$4.01M -206% Jul 1, 2021 Sep 30, 2021 10-Q 2022-10-31
Q2 2021 -$39.7M -$4.38M -$2.82M -181% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 -$36.8M -$29M -$30.1M -2810% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 -$6.76M -$4.33M -$35.6M -114% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-28
Q3 2020 $28.8M -$1.95M +$6.91M +78% Jul 1, 2020 Sep 30, 2020 10-Q 2020-11-13
Q2 2020 $21.9M -$1.56M +$721K +31.6% Apr 1, 2020 Jun 30, 2020 10-Q/A 2020-08-18
Q1 2020 $21.2M $1.07M +$5.13M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
Q4 2019 $16.1M $31.2M +$34.3M Oct 1, 2019 Dec 31, 2019 10-K 2021-04-16
Q3 2019 -$18.3M -$8.86M +$226M +96.2% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-13
Q2 2019 -$244M -$2.28M +$2.88M +55.8% Apr 1, 2019 Jun 30, 2019 10-Q/A 2020-08-18
Q1 2019 -$247M -$4.06M +$3.1M +43.4% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-15
Q4 2018 -$250M -$3.09M +$2.8M +47.5% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-27
Q3 2018 -$253M -$235M -$108M -85% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 -$145M -$5.16M -$3.87M -301% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
Q1 2018 -$141M -$7.16M -$5.62M -366% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-15
Q4 2017 -$136M -$5.89M -$5.07M -617% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-29
Q3 2017 -$131M -$127M -$124M -4914% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-14
Q2 2017 -$6.18M -$1.29M +$836K +39.4% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-14
Q1 2017 -$7.01M -$1.54M +$2.36M +60.6% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-15
Q4 2016 -$9.37M -$822K +$2.09M +71.7% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-01
Q3 2016 -$11.5M -$2.53M +$247K +8.89% Jul 1, 2016 Sep 30, 2016 10-Q/A 2018-02-28
Q2 2016 -$11.7M -$2.12M -$690K -48.2% Apr 1, 2016 Jun 30, 2016 10-Q/A 2018-02-28
Q1 2016 -$11M -$3.9M -$2.09M -115% Jan 1, 2016 Mar 31, 2016 10-Q/A 2018-02-28
Q4 2015 -$8.93M -$2.91M -$1.27M -77.1% Oct 1, 2015 Dec 31, 2015 10-K/A 2018-02-28
Q3 2015 -$7.66M -$2.78M -$2.23M -406% Jul 1, 2015 Sep 30, 2015 10-Q/A 2018-02-28
Q2 2015 -$5.43M -$1.43M -$1.33M -1276% Apr 1, 2015 Jun 30, 2015 10-Q/A 2018-02-28
Q1 2015 -$4.11M -$1.81M -$1.71M -1693% Jan 1, 2015 Mar 31, 2015 10-Q/A 2018-02-28
Q4 2014 -$2.4M -$1.64M -$1.48M -889% Oct 1, 2014 Dec 31, 2014 10-K/A 2018-02-28
Q3 2014 -$920K -$549K -$409K -292% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-13
Q2 2014 -$511K -$104K +$36K +25.7% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-14
Q1 2014 -$547K -$101K +$246K +70.9% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-14
Q4 2013 -$793K -$166K +$572K +77.5% Oct 1, 2013 Dec 31, 2013 10-K 2015-03-31
Q3 2013 -$1.37M -$140K +$1.21M +89.6% Jul 1, 2013 Sep 30, 2013 10-Q 2014-12-17
Q2 2013 -$2.58M -$140K +$890K +86.4% Apr 1, 2013 Jun 30, 2013 10-Q 2015-01-08
Q1 2013 -$3.47M -$347K +$49K +12.4% Jan 1, 2013 Mar 31, 2013 10-Q 2015-01-08
Q4 2012 -$3.51M -$738K +$310K +29.6% Oct 1, 2012 Dec 31, 2012 10-K 2015-01-08
Q3 2012 -$3.82M -$1.35M -$809K -150% Jul 1, 2012 Sep 30, 2012 10-Q 2014-12-17
Q2 2012 -$3.02M -$1.03M -$549K -114% Apr 1, 2012 Jun 30, 2012 10-Q 2014-12-12
Q1 2012 -$2.47M -$396K +$1.46M +78.7% Jan 1, 2012 Mar 31, 2012 10-Q 2014-12-10
Q4 2011 -$3.93M -$1.05M Oct 1, 2011 Dec 31, 2011 10-K 2014-11-18
Q3 2011 -$541K +$113K +17.3% Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-21
Q2 2011 -$481K -$95K -24.6% Apr 1, 2011 Jun 30, 2011 10-Q/A 2012-09-13
Q1 2011 -$1.86M Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-21
Q3 2010 -$654K Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-21
Q2 2010 -$386K Apr 1, 2010 Jun 30, 2010 10-Q/A 2011-09-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.